Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06657768
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-23
Brief Title:
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimers Disease AD
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Placebo-Controlled Single- and Multiple-Ascending Dose Study to Evaluate the Safety Tolerability PK and PD of LY4006895 in Healthy Volunteers and Patients With Early Symptomatic AD
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895 Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimers Disease AD
Blood tests will be performed to check how much LY4006895 gets into the bloodstream and how long it takes the body to eliminate it
This is a 2-part study and will last approximately 29 weeks for Part A and 61 weeks for Part B including a screening period for each part
Blood tests will be performed to check how much LY4006895 gets into the bloodstream and how long it takes the body to eliminate it
This is a 2-part study and will last approximately 29 weeks for Part A and 61 weeks for Part B including a screening period for each part
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None